Liver failure in human immunodeficiency virus – Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy

Marchán‐López, Álvaro; Domínguez-Domínguez, Lourdes; Kessler-Saiz, Pablo; Jarrín-Estupiñán, M.E.

doi:10.1016/j.jhep.2015.10.033

Cited by 12 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If one takes into account data from the United States Acute Liver Failure Study Group, acetaminophen is the most common overall causative agent for ALF with 45.8%, followed by non-acetaminophen DILI with 11%[19], and INH the leading cause of DILI thereafter with 18.8%[20]. These findings come from large cohorts, however the vast majority of DILI research comes in the form of numerous case reports identifying novel hepatotoxic agents; the most recent example from 2016, being hepatotoxicity in HIV/HCV infected patients receiving ledipasvir/sofosbuvir with or without ribavirin[92,93]. …”

Section: Epidemiological Issuesmentioning

confidence: 99%

Drug-induced liver injury: Do we know everything?

Alempijević

Zec

Milosavljević

2017

WJH

View full text Add to dashboard Cite

Interest in drug-induced liver injury (DILI) has dramatically increased over the past decade, and it has become a hot topic for clinicians, academics, pharmaceutical companies and regulatory bodies. By investigating the current state of the art, the latest scientific findings, controversies, and guidelines, this review will attempt to answer the question: Do we know everything? Since the first descriptions of hepatotoxicity over 70 years ago, more than 1000 drugs have been identified to date, however, much of our knowledge of diagnostic and pathophysiologic principles remains unchanged. Clinically ranging from asymptomatic transaminitis and acute or chronic hepatitis, to acute liver failure, DILI remains a leading causes of emergent liver transplant. The consumption of unregulated herbal and dietary supplements has introduced new challenges in epidemiological assessment and clinician management. As such, numerous registries have been created, including the United States Drug-Induced Liver Injury Network, to further our understanding of all aspects of DILI. The launch of LiverTox and other online hepatotoxicity resources has increased our awareness of DILI. In 2013, the first guidelines for the diagnosis and management of DILI, were offered by the Practice Parameters Committee of the American College of Gastroenterology, and along with the identification of risk factors and predictors of injury, novel mechanisms of injury, refined causality assessment tools, and targeted treatment options have come to define the current state of the art, however, gaps in our knowledge still undoubtedly remain.

show abstract

Section: Epidemiological Issuesmentioning

confidence: 99%

Drug-induced liver injury: Do we know everything?

Alempijević

Zec

Milosavljević

2017

WJH

View full text Add to dashboard Cite

show abstract

“…In most cases, drug interactions can be managed and are not a barrier to achieving HCV cure with DAA therapy. Several cases of suspected drug-induced liver injury associated with DAA therapy in HIV/HCV infected persons have bene recently reported, notably in HIV-patients with advanced liver disease receiving lopinavir/ritonavir as part of their ARV regimen [24–26]. The reader is directed to several recent reviews, including the IDSA-AASLD treatment guidelines (www.hcvguidelines.org), for detailed recommendations for how to manage and consider potential ARV-DAA drug interactions [27, 28] (*28) and an online resource (www.hep-druginteractions.org) allows physicians to perform interaction checks in real time.…”

Section: Drug Interactionsmentioning

confidence: 99%

Update in HIV–hepatitis C virus coinfection in the direct acting antiviral era

Meissner

2017

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of Review Availability of direct acting antivirals (DAAs) that demonstrate remarkable clinical efficacy and safety has revolutionized the ability to treat chronic infection with hepatitis C virus (HCV). An equal measure of clinical success has now been achieved in persons co-infected with HCV and the human immunodeficiency virus (HIV), a historically harder to cure cohort with interferon-based therapy. Global goals include identifying all HIV/HCV-infected persons, gaining access to DAA-therapy, preventing de novo and re-infection, and managing the sequelae of chronic infection. This review will discuss advances in the field of HIV/HCV co-infection reported during the last 18 months, and will suggest areas for future investigation. Recent Findings An expanding body of literature has enhanced our understanding of the clinical and epidemiologic issues surrounding HIV/HCV co-infection. DAA therapy for HCV is highly efficacious in HIV/HCV co-infected persons if drug-drug interactions are appropriately considered. Summary Eradicating HCV infection in persons with HIV co-infection can be achieved safely and effectively with available DAAs. Economic and social approaches to enable access and delivery of curative HCV therapy to HIV-infected persons require continued research and resource allocation.

show abstract

“…To the Editor: Hepatotoxicity in HIV/HCV infected patients receiving ledipasvir/sofosbuvir with or without ribavirin has been reported [1][2][3]. We describe three additional cases of probably/highly probable drug-induced liver injury (DILI) with ledipasvir/ sofosbuvir using established causality tools (Naranjo, RUCAM) [4,5].…”

Section: Hepatotoxicity and Potential Drug Interaction With Ledipasvimentioning

confidence: 99%